{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:10:15Z","timestamp":1794834615515,"version":"4.9.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ygyno.2022.01.013","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T23:15:16Z","timestamp":1642893316000},"page":"192-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature"],"prefix":"10.1016","volume":"165","author":[{"given":"Antonio","family":"Raffone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Neola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Maletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Casadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.01.013_bb0005","author":"World Health Organization. GLOBOCAN"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0010","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.013_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.013_bb0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2022.01.013_bb0025","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s12253-020-00829-9","article-title":"TCGA classification of endometrial Cancer: the place of carcinosarcoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.ygyno.2022.01.013_bb0030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00404-020-05542-1","article-title":"Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00404-020-05531-4","article-title":"TCGA molecular subgroups and FIGO grade in endometrial endometrioid carcinoma","volume":"301","author":"Travaglino","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0040","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2020.01.008","article-title":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","volume":"157","author":"Raffone","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.013_bb0045","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12253-019-00784-0","article-title":"TCGA molecular subgroups in endometrial undifferentiated\/dedifferentiated carcinoma","volume":"26","author":"Travaglino","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.013_bb0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/his.13976","article-title":"Clear cell endometrial carcinoma and the TCGA classification","volume":"76","author":"Travaglino","year":"2020","journal-title":"Histopathology."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2021.05.029","article-title":"Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma","author":"Raffone","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2022.01.013_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0b013e31828c63ed","article-title":"Histotype-genotype correlation in 36 high-grade endometrial carcinomas","volume":"37","author":"Hoang","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2022.01.013_bb0075","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ygyno.2022.01.013_bb0080","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7447","key":"10.1016\/j.ygyno.2022.01.013_bb0085","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/aogs.13716","article-title":"BAG3 expression correlates with the grade of dysplasia in squamous intraepithelial lesions of the uterine cervix","volume":"99","author":"Raffone","year":"2020","journal-title":"Acta ObstetGynecol Scand."},{"issue":"11","key":"10.1016\/j.ygyno.2022.01.013_bb0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/apm.12988","article-title":"Nuclear expression of \u03b2-catenin in endometrial hyperplasia as marker of premalignancy","volume":"127","author":"Travaglino","year":"2019","journal-title":"APMIS."},{"issue":"9","key":"10.1016\/j.ygyno.2022.01.013_bb0100","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/apm.12977","article-title":"Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer","volume":"127","author":"Raffone","year":"2019","journal-title":"APMIS."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0110","article-title":"Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)","volume":"38","author":"Singh","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"System. Rev."},{"issue":"9","key":"10.1016\/j.ygyno.2022.01.013_bb0120","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a newinstrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0125","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/his.13776","article-title":"Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria","volume":"74","author":"Travaglino","year":"2019","journal-title":"Histopathology."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00404-019-05103-1","article-title":"Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis","volume":"299","author":"Raffone","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/aogs.13553","article-title":"Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review","author":"Raffone","year":"2019","journal-title":"Acta ObstetGynecol Scand."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG Oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0145","article-title":"Sonographic, demographic characteristics, and the Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) in the prediction of tumor recurrence or progression","author":"Eriksson","year":"2020","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.013_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2019.03.098","article-title":"Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma","volume":"153","author":"Britton","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0155","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/PAS.0000000000001461","article-title":"Endometrial carcinomas with a \u201cserous\u201d component in young women are enriched for DNA mismatch repair deficiency, lynch syndrome, and POLE exonuclease domain mutations","volume":"44","author":"Conlon","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2020.07.102","article-title":"POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women","volume":"159","author":"He","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2017.12.009","article-title":"Racial disparities in molecular subtypes of endometrial cancer","volume":"149","author":"Dubil","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2022.01.013_bb0170","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.14370","article-title":"Molecular characterization of second primary endometrial cancer","volume":"40","author":"Haraga","year":"2020","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.013_bb0175","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41379-020-0626-9","article-title":"Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups","volume":"34","author":"Rau","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0185","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/path.4947","article-title":"The genetic landscape of endometrial clear cell carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.ygyno.2022.01.013_bb0190","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 Endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.ygyno.2022.01.013_bb0195","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2022.01.013_bb0200","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J. Pathol. Clin. Res."},{"issue":"9","key":"10.1016\/j.ygyno.2022.01.013_bb0205","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.013_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2018.01.008","article-title":"The NCI-MATCH trial and precision medicine in gynecologic cancers","volume":"148","author":"Barroilhet","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2022.01.013_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2017.02.001","article-title":"Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH","volume":"41","author":"Coyne","year":"2017","journal-title":"Curr. Probl. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2022.01.013_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2016.03.017","article-title":"Precision medicine","volume":"141","author":"Coleman","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0225","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"1-14","author":"McAlpine","year":"2021","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2022.01.013_bb0230","first-page":"1","article-title":"Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer","volume":"2021","author":"Loukovaara","year":"2020","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.ygyno.2022.01.013_bb0235","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.01.013_bb0240","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2021.06.002","article-title":"The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients","volume":"162","author":"Ronsini","year":"2021","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:42Z","timestamp":1758772722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0090825822000208"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}